{"id":144451,"date":"2014-09-24T18:44:27","date_gmt":"2014-09-24T22:44:27","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/opportunities-to-reduce-patient-burden-associated-with-breast-cancer-screening.php"},"modified":"2014-09-24T18:44:27","modified_gmt":"2014-09-24T22:44:27","slug":"opportunities-to-reduce-patient-burden-associated-with-breast-cancer-screening","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/genetic-engineering\/opportunities-to-reduce-patient-burden-associated-with-breast-cancer-screening.php","title":{"rendered":"Opportunities to reduce patient burden associated with breast cancer screening"},"content":{"rendered":"<p><p>    PUBLIC RELEASE DATE:  <\/p>\n<p>    23-Sep-2014  <\/p>\n<p>    Contact: Kathryn Ryan    <a href=\"mailto:kryan@liebertpub.com\">kryan@liebertpub.com<\/a>    914-740-2100    Mary Ann Liebert, Inc.\/Genetic    Engineering News    @LiebertOnline<\/p>\n<p>    New Rochelle, NY, September 23, 2014New technology and better    screening strategies can lower the rate of false-positive    results, which impose a substantial financial and psychological    burden on women. The many misperceptions about breast cancer    screening options and risks, the benefits and costs of    screening, and the need for new approaches and better education    are discussed in a series of articles in a supplement to    Journal of Women's Health, a peer-reviewed publication    from Mary Ann Liebert, Inc., publishers. The supplement is    available free on the Journal of Women's Health website    at <a href=\"http:\/\/online.liebertpub.com\/toc\/jwh\/23\/S1\" rel=\"nofollow\">http:\/\/online.liebertpub.com\/toc\/jwh\/23\/S1<\/a>.  <\/p>\n<p>    In the article \"The    Patient Burden of Screening Mammography Recall,\" the    authors report that among more than 1.7 million women aged    40-75 years who underwent screening mammography and were not    diagnosed with breast cancer, 15% were recalled for further    testing. The cumulative risk of a false-positive result after    10 years of annual screening mammograms is an estimated 61%.    Coauthors Matthew Alcusky, PharmD, MS, Janice Clarke, RN, BBA,    and Alexandria Skoufalos, EdD, Jefferson School of Population    Health; Liane Philpotts, MD, FSBI, Yale University School of    Medicine; and Machaon Bonafede, PhD, MPH, Truven Health    Analytics, evaluate the direct cost burden of recall, the    indirect costs associated with missed work time, travel, and    substitute caregivers, for example, and the physical or    psychological effects of a false-positive result, which may    include unnecessary anxiety and reduced quality of life.  <\/p>\n<p>    In an accompanying review article on \"Understanding    Patient Options, Utilization Patterns and Burdens Associated    with Breast Cancer Screening,\" authors Susan C. Harvey, MD,    Johns Hopkins Medical Institutions; Sharon Mass, MD, FACOG,    Morristown Obstetrics and Gynecology Associates; and Ashok    Vegesna, PharmD, Janice Clarke, RN, BBA, and Alexandria    Skoufalos, EdD, Jefferson School of Population Health,    attribute much of the confusion women face in making informed    decisions about breast cancer screening and recall options to a    lack of consensus among the organizations developing screening    guidelines and the mixed messages they deliver. The authors    call for a more thoughtful approach to breast cancer screening    and research that takes into account the tangible and    intangible costs that women now bear.  <\/p>\n<p>    \"The articles in this supplement are timely and reveal    surprisingly complex issues,\" says Susan C. Harvey, MD, in her    Editorial, \"The    Charge and the Challenges of Breast Cancer Screening.\"    Collectively, the articles \"illustrate the need for a more    tailored approach to breast cancer awareness, education, and    screening. The goal is to make appropriate screening and    diagnosis easier on women and more responsive to the changing    face of value-based health care.\"  <\/p>\n<p>    \"The direct and indirect cost burden of inconclusive    mammography screenings and recalls is significant and indicates    a need for new approaches to breast cancer screening,\" says    Susan G. Kornstein, MD, Editor-in-Chief of Journal of    Women's Health, Executive Director of the Virginia    Commonwealth University Institute for Women's Health, Richmond,    VA, and President of the Academy of Women's Health.  <\/p>\n<p>    ###  <\/p>\n<p>    The supplement was funded by an educational grant from Hologic,    Inc.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Continued here:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.eurekalert.org\/pub_releases\/2014-09\/mali-otr092314.php\/RK=0\/RS=aahGYAUr1zWrWkkRkUPW_UYavI0-\" title=\"Opportunities to reduce patient burden associated with breast cancer screening\">Opportunities to reduce patient burden associated with breast cancer screening<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> PUBLIC RELEASE DATE: 23-Sep-2014 Contact: Kathryn Ryan <a href=\"mailto:kryan@liebertpub.com\">kryan@liebertpub.com<\/a> 914-740-2100 Mary Ann Liebert, Inc.\/Genetic Engineering News @LiebertOnline New Rochelle, NY, September 23, 2014New technology and better screening strategies can lower the rate of false-positive results, which impose a substantial financial and psychological burden on women.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/genetic-engineering\/opportunities-to-reduce-patient-burden-associated-with-breast-cancer-screening.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[3],"tags":[],"class_list":["post-144451","post","type-post","status-publish","format-standard","hentry","category-genetic-engineering"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/144451"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=144451"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/144451\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=144451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=144451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=144451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}